| Particulars (Rupees in Crores.) | Sept-2024 | Jun-2024 | Mar-2024 | Dec-2023 | Sept-2023 |
|---|---|---|---|---|---|
Gross Sales | 2,831 | 2,815 | 2,695 | 2,691 | 2,628 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,831 | 2,815 | 2,695 | 2,691 | 2,628 |
Other Operating Income | 58 | 44 | 50 | 41 | 32 |
Other Income | -16 | 24 | 31 | 55 | 26 |
Total Income | 2,873 | 2,883 | 2,776 | 2,787 | 2,686 |
Total Expenditure | 1,950 | 1,955 | 1,862 | 1,863 | 1,835 |
PBIDT | 923 | 928 | 914 | 924 | 851 |
Interest | 64 | 75 | 80 | 80 | 91 |
PBDT | 859 | 853 | 834 | 844 | 760 |
Depreciation | 198 | 197 | 203 | 213 | 201 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 156 | 126 | 142 | 106 | 120 |
Deferred Tax | 52 | 73 | 40 | 82 | 53 |
Reported Profit After Tax | 453 | 457 | 449 | 443 | 386 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 453 | 457 | 449 | 443 | 386 |
Extra-ordinary Items | 0 | 0 | 0 | 61.78 | 0 |
Adjusted Profit After Extra-ordinary item | 453 | 457 | 449 | 381.22 | 386 |
EPS (Unit Curr.) | 13.37 | 13.51 | 13.27 | 13.1 | 11.39 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 440 | 0 |
Equity | 169.23 | 169.23 | 169.23 | 169.23 | 169.23 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 32.6 | 32.96 | 33.91 | 34.33 | 32.38 |
PBDTM(%) | 30.34 | 30.3 | 30.94 | 31.36 | 28.91 |
PATM(%) | 16 | 16.23 | 16.66 | 16.46 | 14.68 |
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Bajaj Finance, Vedanta, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
